Drug Eluting Contact Lenses

药物洗脱隐形眼镜

• 批准号: 8531942
• 负责人: Joseph B. Ciolino
• 金额: $ 23万
• 依托单位: MASSACHUSETTS EYE AND EAR INFIRMARY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8531942
• 关键词: Adverse effects; Animal Disease Models; Animal Model; Animals; Anti-Bacterial Agents; Antibiotic Therapy; Antibiotics; Aqueous Humor; Bandage; Basic Science; Biological; Chemical Engineering; Clinical; Competence; Contact Lenses; Cornea; Development; Devices; Disease; Doctor of Philosophy; Drops; Drug Combinations; Drug Delivery Systems; Drug Evaluation; Drug usage; Ear; Education; Evaluation; Eye; Eye diseases; Eyedrops; Fellowship; Film; Fostering; Glaucoma; Goals; Hypersensitivity; In Vitro; Institutes; Instruction; Keratitis; Kinetics; Massachusetts; Medical; Mentors; Microbiology; Ophthalmologic Surgical Procedures; Ophthalmology; Oryctolagus cuniculus; Patients; Pharmaceutical Preparations; Physiological; Polymers; Process; Research; Research Personnel; Research Project Grants; Residencies; Safety; Scientist; Self-Administered; Solutions; Staging; System; Techniques; Technology; Time; Tissue Engineering; Training; Training and Education; Universities; Work; absorption; biomaterial compatibility; career development; compliance behavior; controlled release; design; drug modification; in vivo; interest; member; next generation; programs; research study; skills; treatment effect

DESCRIPTION (provided by applicant): After completing my ophthalmology residency, I began a unique 2 year cornea fellowship at Massachusetts Eye & Ear Infirmary (MEEI). During the first year, I worked nearly exclusively on basic science research at Massachusetts Institute of Technology (MIT) in the Langer Lab, mentored by Daniel Kohane, MD, PhD and Claes Dohlman, MD, PhD. Along with cornea tissue engineering projects, we developed a drug-eluting contact lens. My principal clinical interest is in the treatment of cornea diseases. For most patients there is no alternative to topical solutions (drops) for medications such as antibiotics used after eye surgery. In addition, bandage contact lenses are often used in conjunction with antibiotics. This research will endeavor to create a new mode of ocular drug delivery: drug-eluting contact lenses. The benchtop research will continue with experiments in design modification and drug release studies before progressing to animal studies. The in vivo research follows a natural progression from studying the drug-eluting contact lens's effect under normal, physiologic conditions to its use as a treatment of disease (bacterial keratitis and glaucoma). This mentored research project in chemical engineering, microbiology, and ocular drug delivery, in conjunction with the appropriate coursework, aims to develop competence in biotechnological approaches to medical problems and ocular drug delivery. I will continue the research under my current mentor Daniel Kohane, an expert in polymer drug delivery, and James Chodosh, an expert in animal disease models. MEEI is a leader in ophthalmic research. MIT's Langer lab offers a world-class education in polymer technology. The research will be conducted with the support of a team of scientists and clinician-scientists who have mentored over a 100 private investigators in university settings. The personal relationship that I already have with the team members will be enriched by their expertise in their respective fields. They will help me to accomplish the research aims and mentor my career development. Thus, this program will foster the abilities and approach necessary to train me to become an independent investigator and possibly a leader in the next generation of clinician-scientists. RELEVANCE (See instructions): Drug eluting contact lenses would provide an alternative to eye drops, which are inefficient delivery system that can be difficult to self-administer, contain allergy-inducing preservatives, have a limited contact time with the eye, and cannot be used for many medications. More importantly, they would offer the possibility of treating eye diseases with a host of medications that cannot currently be delivered in a drop form.

描述（由申请人提供）：完成眼科住院医师培训后，我在马萨诸塞州眼耳医院 (MEEI) 开始了为期 2 年的独特角膜研究金。第一年，我在麻省理工学院 (MIT) 的 Langer 实验室几乎全部从事基础科学研究，由 Daniel Kohane 医学博士和 Claes Dohlman 医学博士指导。除了角膜组织工程项目，我们还开发了药物洗脱隐形眼镜。我的主要临床兴趣是角膜疾病的治疗。对于大多数患者来说，除了眼科手术后使用的抗生素等药物外，没有其他选择。此外，绷带隐形眼镜常与抗生素联合使用。这项研究将致力于创造一种新的眼部药物输送模式：药物洗脱隐形眼镜。台式研究将继续进行设计修改和药物释放研究的实验，然后再进行动物研究。体内研究遵循从研究药物洗脱隐形眼镜在正常生理条件下的效果到用于治疗疾病（细菌性角膜炎和青光眼）的自然发展。该指导研究项目涉及化学工程、微生物学和眼部药物输送，并结合适当的课程，旨在培养利用生物技术方法解决医疗问题和眼部药物输送的能力。我将在现任导师聚合物药物输送专家 Daniel Kohane 和动物疾病模型专家 James Chodosh 的指导下继续研究。 MEEI 是眼科研究领域的领导者。麻省理工学院的兰格实验室提供世界一流的聚合物技术教育。这项研究将在科学家和临床科学家团队的支持下进行，他们曾在大学环境中指导过 100 多名私人调查员。我与团队成员之间已有的个人关系将因他们在各自领域的专业知识而变得更加丰富。他们将帮助我实现研究目标并指导我的职业发展。因此，这个项目将培养必要的能力和方法，训练我成为一名独立的研究者，并可能成为下一代临床医生科学家的领导者。相关性（参见说明）：药物洗脱隐形眼镜将提供滴眼剂的替代品，滴眼剂的输送系统效率低下，难以自行给药，含有诱发过敏的防腐剂，与眼睛的接触时间有限，并且无法自行给药。用于许多药物。更重要的是，它们将提供用目前无法以滴剂形式提供的多种药物治疗眼部疾病的可能性。

项目成果

An evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eye.

Retaine™ 眼用乳剂在治疗干眼患者泪膜稳定性和眼表染色方面的评价。

• 发表时间: 2015
• 作者: Ousler 3rd, George;Devries, Douglas K;Karpecki, Paul M;Ciolino, Joseph B
• 通讯作者: Ciolino, Joseph B

Retention of the Boston keratoprosthesis type 1: multicenter study results.

波士顿角膜假体 1 型的保留：多中心研究结果。

• 发表时间: 2013-06
• 影响因子: 13.7
• 作者: Ciolino, Joseph B;Belin, Michael W;Todani, Amit;Al;Rudnisky, Christopher J;Boston Keratoprosthesis Type 1 Study Group
• 通讯作者: Boston Keratoprosthesis Type 1 Study Group

UV cross-linking of donor corneas confers resistance to keratolysis.

供体角膜的紫外线交联可抵抗角质层分离。

• 发表时间: 2014-09
• 影响因子: 2.8
• 作者: Arafat, Samer N;Robert, Marie;Shukla, Anita N;Dohlman, Claes H;Chodosh, James;Ciolino, Joseph B
• 通讯作者: Ciolino, Joseph B

Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology.

眼科突破性治疗的视网膜植入和医疗保险报销政策。

• 发表时间: 2015-04
• 影响因子: 8.1
• 作者: Hwang, Thomas J;Ciolino, Joseph B
• 通讯作者: Ciolino, Joseph B

Biologic keratoprosthesis materials.

生物角膜假体材料。

• 发表时间: 2009
• 作者: Ciolino, Joseph B;Dohlman, Claes H
• 通讯作者: Dohlman, Claes H